JP2023531970A5 - - Google Patents

Info

Publication number
JP2023531970A5
JP2023531970A5 JP2022579736A JP2022579736A JP2023531970A5 JP 2023531970 A5 JP2023531970 A5 JP 2023531970A5 JP 2022579736 A JP2022579736 A JP 2022579736A JP 2022579736 A JP2022579736 A JP 2022579736A JP 2023531970 A5 JP2023531970 A5 JP 2023531970A5
Authority
JP
Japan
Prior art keywords
composition according
group
cancer
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022579736A
Other languages
English (en)
Japanese (ja)
Other versions
JP7804596B2 (ja
JP2023531970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038339 external-priority patent/WO2021262627A1/en
Publication of JP2023531970A publication Critical patent/JP2023531970A/ja
Publication of JP2023531970A5 publication Critical patent/JP2023531970A5/ja
Application granted granted Critical
Publication of JP7804596B2 publication Critical patent/JP7804596B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022579736A 2020-06-23 2021-06-22 ヘテロアリール－ビフェニルアミド誘導体を用いて癌を処置する方法 Active JP7804596B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042807P 2020-06-23 2020-06-23
US63/042,807 2020-06-23
PCT/US2021/038339 WO2021262627A1 (en) 2020-06-23 2021-06-22 Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Publications (3)

Publication Number Publication Date
JP2023531970A JP2023531970A (ja) 2023-07-26
JP2023531970A5 true JP2023531970A5 (https=) 2024-06-07
JP7804596B2 JP7804596B2 (ja) 2026-01-22

Family

ID=79022859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579736A Active JP7804596B2 (ja) 2020-06-23 2021-06-22 ヘテロアリール－ビフェニルアミド誘導体を用いて癌を処置する方法

Country Status (14)

Country Link
US (3) US20210393759A1 (https=)
EP (1) EP4167991A4 (https=)
JP (1) JP7804596B2 (https=)
KR (1) KR20230040993A (https=)
CN (1) CN116472045B (https=)
AU (1) AU2021297216B2 (https=)
BR (1) BR112022026397A2 (https=)
CA (1) CA3187605A1 (https=)
CL (1) CL2022003716A1 (https=)
CO (1) CO2023000703A2 (https=)
IL (1) IL299206A (https=)
MX (1) MX2022016554A (https=)
TW (1) TW202216694A (https=)
WO (1) WO2021262627A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
ES3064674T3 (en) 2019-10-16 2026-04-28 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448938A (zh) * 2009-03-27 2012-05-09 阿迪生物科学公司 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺
SG11201402004YA (en) * 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
JP7101678B2 (ja) * 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
CN106674136B (zh) * 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
US10919852B2 (en) * 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
CA3092362A1 (en) * 2017-10-19 2019-04-25 Tempest Therapeutics, Inc. Picolinamide compounds
CR20200347A (es) * 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US10568874B2 (en) * 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
JP7736678B2 (ja) * 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド

Similar Documents

Publication Publication Date Title
JP2023531970A5 (https=)
AU2020394767B2 (en) Spiro compound serving as ERK inhibitor, and application thereof
JP2025023997A (ja) Ｆａｋ阻害剤およびその併用薬物
JP2023533938A5 (https=)
JP2023040165A5 (https=)
US11685757B2 (en) Pharmaceutical co-crystal composition and use thereof
US12030897B2 (en) Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof
KR20180017013A (ko) K-Ras 조절제
CN105793261A (zh) 吡唑并嘧啶化合物
JP2023531709A5 (https=)
RU2018129344A (ru) Производное хиназолинона, способ его получения, фармацевтическая композиция и применения
JP2021536492A (ja) イルジン類似体、それらの使用、およびそれらを合成する方法
JP2021514395A5 (https=)
JP2017534657A (ja) 新型シチジン誘導体およびその適用
CN110357885A (zh) 一种蝶啶类化合物及其在药学上的应用
US20220227758A1 (en) Imidazopyridine compound as irak4 inhibitor
US12448378B2 (en) Fluoropyrrolopyridine compound and application thereof
JP2008516989A (ja) 組成物及び抗腫瘍剤としてのその使用
CN110845408A (zh) 同位素富集的乐伐替尼
CN116514728A (zh) 一种喹唑啉衍生物及其用途
JP2024538128A5 (https=)
RU2011136855A (ru) Производные бензотиазолов и бензимидазолов, содержащие 6-nh-замещенные триазолопиридазинсульфанил в положении 6: получение, применение в качестве лекарственных средств и применение в качестве ингибиторов мет
US20190106396A1 (en) Bis-diazeniumdiolate compounds as anti-cancer agents
CN105209032A (zh) 使用转录因子调节剂治疗癌症和其他病症
JP2022512874A5 (https=)